ArQule (NASDAQ:ARQL) released its earnings results on Monday, March 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.09), Bloomberg Earnings reports. During the same period last year, the business posted ($0.10) earnings per share.
Shares of ArQule (NASDAQ ARQL) traded up $0.01 during mid-day trading on Wednesday, hitting $1.84. The company’s stock had a trading volume of 54,343 shares, compared to its average volume of 235,354. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 1.03. ArQule has a 52 week low of $0.92 and a 52 week high of $1.98.
Several hedge funds have recently made changes to their positions in the business. BVF Inc. IL lifted its position in shares of ArQule by 122.1% during the 4th quarter. BVF Inc. IL now owns 16,436,912 shares of the biotechnology company’s stock worth $27,121,000 after buying an additional 9,036,784 shares during the period. First Eagle Investment Management LLC lifted its position in shares of ArQule by 5.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock worth $13,807,000 after buying an additional 591,421 shares during the period. Renaissance Technologies LLC lifted its position in shares of ArQule by 15.9% during the 4th quarter. Renaissance Technologies LLC now owns 2,295,703 shares of the biotechnology company’s stock worth $3,788,000 after buying an additional 315,203 shares during the period. Point72 Asset Management L.P. bought a new position in shares of ArQule during the 3rd quarter worth approximately $2,220,000. Finally, Deutsche Bank AG bought a new position in shares of ArQule during the 4th quarter worth approximately $390,000. Institutional investors own 67.05% of the company’s stock.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.